Oxaliplatin: A review of evolving concepts

被引：59

作者：

Mani, S

Graham, MA

Bregman, DB

Ivy, P

Chaney, SG

机构：

[1] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA

[2] Weiler Hosp Montefiore Med Ctr, Dept Oncol, Bronx, NY 10461 USA

[3] Dept Clin Pharmacokinet, Malvern, PA USA

[4] Drug Metab Sanofi Synthelabo, Malvern, PA USA

[5] Albert Einstein Coll Med, Dept Pathol, Bronx, NY USA

[6] Natl Canc Inst, Canc Therapy Evaluat Program, Bethesda, MD USA

[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC USA

来源：

CANCER INVESTIGATION | 2002年 / 20卷 / 02期

关键词：

D O I：

10.1081/CNV-120001152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：246 / 263

页数：18

共 179 条

[1] Raltitrexed (Tomudex™) in combination with platinum-based agents and/or anthracyclines:: Preliminary results of phase I clinical trials [J].

Armand, JP ;

Seymour, L ;

Evans, TRJ .

EUROPEAN JOURNAL OF CANCER, 1999, 35 :S14-S18

[2]

Becouarn Y, 1998, SEMIN ONCOL, V25, P23

[3] 'Tomudex' (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients:: An active combination [J].

Bennouna, J ;

Seitz, JF ;

Paillot, B ;

Gamelin, E ;

François, E ;

Conroy, T ;

Raoul, JL ;

Becouarn, Y ;

Cvitkovic, FB ;

Nasca, S ;

Ychou, M ;

Smith, M ;

Douillard, JY ;

Fandi, A .

EUROPEAN JOURNAL OF CANCER, 1999, 35 :S75-S75

[4]

Bleiberg H, 1998, SEMIN ONCOL, V25, P32

[5] FORMATION OF DNA-ADDUCTS BY THE ANTICANCER DRUG CARBOPLATIN - DIFFERENT NUCLEOTIDE-SEQUENCE PREFERENCES IN-VITRO AND IN CELLS [J].

BLOMMAERT, FA ;

VANDIJKKNIJNENBURG, HCM ;

DIJT, FJ ;

DENENGELSE, L ;

BAAN, RA ;

BERENDS, F ;

FICHTINGERSCHEPMAN, AMJ .

BIOCHEMISTRY, 1995, 34 (26) :8474-8480

[6]

Bokemeyer C, 1999, INT J CANCER, V83, P848, DOI 10.1002/(SICI)1097-0215(19991210)83:6<848::AID-IJC29>3.0.CO

[7]

2-#

[8] Oxaliplatin added to 5-fluorouracil-based therapy (5-FU ± FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC):: Results from the European compassionate-use program [J].

Brienza, S ;

Bensmaïne, MA ;

Soulié, P ;

Louvet, C ;

Gamelin, E ;

François, E ;

Ducreux, M ;

Marty, M ;

André, T ;

de Braud, F ;

Bleiberg, H ;

Ségal, V ;

Itzhaki, M ;

Cvitkovic, E .

ANNALS OF ONCOLOGY, 1999, 10 (11) :1311-1316

[9]

BRIENZA S, 1995, P AN M AM SOC CLIN, V14, pA513

[10] Biweekly docetaxel (DOC), gemcitabine (GEM), oxaliplatin (LOHP) in heavily pretreated patients with solid tumors -: Preliminary results of a phase I study [J].

Büchele, T ;

Grothey, A ;

Voigt, W ;

Kegel, T ;

Rie, C ;

Wunderlich, D ;

Schmoll, HJ .

EUROPEAN JOURNAL OF CANCER, 1999, 35 :S288-S288

← 1 2 3 4 5 6 7 8 9 10 →